 Amgen’s rare disease drug Tavneos is under mounting regulatory scrutiny, with the FDA warning of serious liver injuries, including some fatalities, among patients who received the drug. 
Content mobilized by FeedBlitz RSS Services, the premium FeedBurner alternative. |
